HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis
USA - NASDAQ:HRMY - US4131971040 - Common Stock
34.03 USD
-0.26 (-0.76%)
34.03 USD
0 (0%)
Taking everything into account, HRMY scores 8 out of 10 in our fundamental rating. HRMY was compared to 192 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HRMY could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year HRMY was profitable.
HRMY had a positive operating cash flow in the past year.
Of the past 5 years HRMY 4 years were profitable.
HRMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HRMY has a better Return On Assets (15.37%) than 95.83% of its industry peers.
With an excellent Return On Equity value of 22.23%, HRMY belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HRMY is above the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
Looking at the Profit Margin, with a value of 22.48%, HRMY belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
HRMY's Profit Margin has improved in the last couple of years.
HRMY has a Operating Margin of 27.32%. This is amongst the best in the industry. HRMY outperforms 92.71% of its industry peers.
HRMY's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 77.70%, HRMY belongs to the top of the industry, outperforming 82.81% of the companies in the same industry.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
HRMY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HRMY has less shares outstanding
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.22 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY's Altman-Z score of 5.22 is fine compared to the rest of the industry. HRMY outperforms 79.17% of its industry peers.
HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
HRMY has a Debt to FCF ratio of 0.57. This is amongst the best in the industry. HRMY outperforms 96.35% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that HRMY is not too dependend on debt financing.
HRMY's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. HRMY outperforms 46.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.22 |
ROIC/WACC1.91
WACC9.02%
2.3 Liquidity
HRMY has a Current Ratio of 3.75. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Current ratio (3.75) which is comparable to the rest of the industry.
A Quick Ratio of 3.72 indicates that HRMY has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.72, HRMY is in the better half of the industry, outperforming 60.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.71% over the past year.
Measured over the past years, HRMY shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.61% on average per year.
Looking at the last year, HRMY shows a very strong growth in Revenue. The Revenue has grown by 21.13%.
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
Based on estimates for the next years, HRMY will show a very strong growth in Earnings Per Share. The EPS will grow by 34.90% on average per year.
HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.35% yearly.
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.70, the valuation of HRMY can be described as reasonable.
HRMY's Price/Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 89.58% of the companies in the same industry.
HRMY is valuated cheaply when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.25, which indicates a very decent valuation of HRMY.
89.58% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
HRMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.7 | ||
| Fwd PE | 8.25 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 96.88% of the companies are valued more expensively.
HRMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HRMY is cheaper than 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.59 | ||
| EV/EBITDA | 5.72 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
HRMY's earnings are expected to grow with 27.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y28.23%
EPS Next 3Y27.97%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
34.03
-0.26 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.62%
Inst Owner Change-7.77%
Ins Owners0.52%
Ins Owner Change-104.37%
Market Cap1.96B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target44.88 (31.88%)
Short Float %7.36%
Short Ratio4.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)-1.22%
PT rev (3m)-12.48%
EPS NQ rev (1m)-6.79%
EPS NQ rev (3m)-1.91%
EPS NY rev (1m)2.28%
EPS NY rev (3m)-3.02%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.7 | ||
| Fwd PE | 8.25 | ||
| P/S | 2.37 | ||
| P/FCF | 6.59 | ||
| P/OCF | 6.58 | ||
| P/B | 2.34 | ||
| P/tB | 2.65 | ||
| EV/EBITDA | 5.72 |
EPS(TTM)3.18
EY9.34%
EPS(NY)4.13
Fwd EY12.13%
FCF(TTM)5.16
FCFY15.17%
OCF(TTM)5.17
OCFY15.2%
SpS14.36
BVpS14.52
TBVpS12.86
PEG (NY)0.35
PEG (5Y)N/A
Graham Number32.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.22 |
F-Score6
WACC9.02%
ROIC/WACC1.91
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year36.94%
EBIT Next 3Y27.36%
EBIT Next 5Y22.83%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.7 and the Price/Book (PB) ratio is 2.34.